Sugi Predict

Sugi Predict / Compounds / SCHEMBL721793

SCHEMBL721793

SCHEMBL721793

NC(=O)c1c(C(=O)O)[nH]c2ccccc12

nearest known ligand 0.58

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAP2 P11137 1/20 0.58
▸ KDM4E B2RXH2 6/20 0.57
▸ ALDH1A1 P00352 3/20 0.57
▸ HPGD P15428 2/20 0.57
▸ TDP1 Q9NUW8 1/20 0.54
▸ MEN1 O00255 3/20 0.53
▸ KMT2A Q03164 3/20 0.53
▸ POLB P06746 1/20 0.53
▸ FOLH1 Q04609 1/20 0.51
▸ GAA P10253 2/20 0.47
▸ MAPT P10636 1/20 0.47
▸ GFER P55789 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ MCL1 Q07820 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18824256 0.89 MAP2 (0.62) MAP2KDM4EALDH1A1HPGDTDP1
SCHEMBL87871 0.87 KDM4E (0.65) MAP2KDM4EALDH1A1HPGDTDP1
SCHEMBL4740373 0.86 KDM4E (0.58) MAP2KDM4EALDH1A1HPGDTDP1
SCHEMBL1253405 0.83 MAP2 (0.53) MAP2KDM4EALDH1A1HPGDTDP1
Hydrochloric Acid SCHEMBL1504227 0.82 MAP2 (0.51) MAP2KDM4EALDH1A1HPGDTDP1
SCHEMBL8806930 0.82 KDM4E (0.57) MAP2KDM4EALDH1A1HPGDTDP1
SCHEMBL29955046 0.82 KDM4E (0.66) MAP2KDM4EALDH1A1HPGDTDP1
SCHEMBL2339411 0.82 KDM4E (0.66) MAP2KDM4EALDH1A1HPGDTDP1
SCHEMBL3246965 0.80 NR4A2 (0.60) MAP2KDM4EALDH1A1HPGDMEN1
SCHEMBL29050101 0.80 MEN1 (0.61) MAP2KDM4EALDH1A1TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012025155-A1 HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES NOVARTIS AG (CH) 2012-03-01 — — WO disclosed
CN-1741821-B Compositions for cancer treatment ENGENE INC 2011-08-10 — — CN disclosed
US-20110086885-A1 Indole-2-carboxylic acid amides PROSIDION LIMITED (GB) 2011-04-14 — — US disclosed
US-20110086885-A1 Indole-2-carboxylic acid amides PROSIDION LIMITED (GB) 2011-04-14 — — US disclosed
US-20090042949-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2009-02-12 — — US disclosed
CN-101301294-A Combinated inhibitors of FBP-ase and antidiabetic agents for diabetes treatment METABEHJSIS TERAP JUTIKS INK (US) 2008-11-12 — — CN disclosed
CN-100396283-C Combination of FBP enzyme inhibitor and antidiabetic agent for treating diabetes METABASIS THERAPEUTICS INC (US) 2008-06-25 — — CN disclosed
US-7378431-B2 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-05-27 — — US disclosed
US-7375116-B2 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-05-20 — — US disclosed
US-7365083-B2 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-04-29 — — US disclosed
US-20050159451-A1 Amide derivatives as NMDA receptor antagonists HORVATH CSILLA (HU) 2005-07-21 — — US disclosed
US-6919355-B2 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2005-07-19 — — US disclosed
US-20050113359-A1 Amide derivatives as NMDA receptor antagonists HORVATH CSILLA (HU) 2005-05-26 — — US disclosed
US-20050113361-A1 Amide derivatives as NMDA receptor antagonists HORVATH CSILLA (HU) 2005-05-26 — — US disclosed
US-20050113360-A1 Amide derivatives as NMDA receptor antagonists HORVATH CSILLA (HU) 2005-05-26 — — US disclosed
WO-2005040111-A2 COMBINATORIAL LIBRARY OF 3-ARYL-1H-INDOLE-2-CARBOXYLIC ACIDS F. HOFFMANN-LA ROCHE AG (DE) 2005-05-06 — — WO disclosed
CN-1599612-A Combination of FBP enzyme inhibitor and antidiabetic agent for treating diabetes METABASIS THERAPEUTICS INC (US) 2005-03-23 — — CN disclosed
US-20030199552-A1 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. 2003-10-23 — — US disclosed
CN-1228695-A Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta [b] benzofurans LILLY CO ELI (US) 1999-09-15 — — CN disclosed
CN-1142492-A Substituted N-(indole-2-carbonyl)-glycinamides and derivatives as antidiabetic agents PFIZER (US) 1997-02-12 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113361-A1 Amide derivatives as NMDA receptor antagonists GRIN1, GRIN3A, GRIN2B MAP2 2464/4885KDM4E 934/4885ALDH1A1 3399/4885
US-20110086885-A1 Indole-2-carboxylic acid amides IDO2, IDO1, CPT1A MAP2 1287/4885KDM4E 3063/4885ALDH1A1 512/4885
US-20050113360-A1 Amide derivatives as NMDA receptor antagonists GRIN1, GRIN3A, GRIN2B MAP2 1451/4885KDM4E 1346/4885ALDH1A1 3195/4885
US-20050159451-A1 Amide derivatives as NMDA receptor antagonists GRIN1, GRIN3A, GRIN2B MAP2 1348/4885KDM4E 1242/4885ALDH1A1 3627/4885
US-20050113359-A1 Amide derivatives as NMDA receptor antagonists GRIN1, GRIN3A, GRIN2B MAP2 2440/4885KDM4E 885/4885ALDH1A1 3307/4885
US-20030199552-A1 Amide derivatives as NMDA receptor antagonists GRIN1, GRIN3A, GRIN2C MAP2 2924/4885KDM4E 1215/4885ALDH1A1 1852/4885
US-20090042949-A1 Indoles Useful in the Treatment of Inflammation IDO1, IDO2, AREG MAP2 38/4885KDM4E 1331/4885ALDH1A1 2466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.